RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Xynomic Pharmaceuticals Holdings Stock

Xynomic Pharmaceuticals Holdings Employees 2024

Xynomic Pharmaceuticals Holdings Employees

0

Ticker

XYNO

ISIN

US98421X1028

In 2024, Xynomic Pharmaceuticals Holdings employed 0 people, a 0% change from the 0 number of employees in the previous year.

Xynomic Pharmaceuticals Holdings Aktienanalyse

What does Xynomic Pharmaceuticals Holdings do?

Xynomic Pharmaceuticals Holdings Inc is a biopharmaceutical company based in New York City that focuses on the development and marketing of innovative cancer therapies. The company was founded in 2016 and has since become a leading player in the industry. In this post, we would like to tell you more about the history and business model of Xynomic Pharmaceuticals, as well as the various products that the company offers. History of Xynomic Pharmaceuticals Holdings Inc Xynomic Pharmaceuticals was founded in 2016 by an experienced team of pharmaceutical industry experts, including Dr. Peng Wang, the CEO of the company. The company's goal from the beginning was to develop and bring to market innovative cancer drugs to help patients around the world. The company has made significant progress since its inception and now has an impressive portfolio of cancer therapies. Business model of Xynomic Pharmaceuticals The business model of Xynomic Pharmaceuticals is focused on developing high-quality cancer therapies and bringing them to market. The company works closely with leading academic institutions and commercial partners to identify and explore innovative concepts for combating cancer. Xynomic Pharmaceuticals' products are designed to treat specific types of cancer and be tailored to the needs of patients worldwide. Products of Xynomic Pharmaceuticals Xynomic Pharmaceuticals' portfolio includes a variety of innovative cancer therapies tailored to different types of cancer. One example is the drug Abexinostat, which is currently in phase 3 clinical trials and is used to treat peripheral T-cell lymphoma (PTCL). Abexinostat is an oral medication that targets epigenetic enzymes involved in the development of cancer. The drug has the potential to extend the survival of patients with PTCL and is a promising new treatment option for this serious disease. Another product of Xynomic Pharmaceuticals is the drug XP-102, which is used to treat fatty liver diseases. Fatty liver disease, also known as non-alcoholic fatty liver disease (NAFLD), is a common condition that occurs due to factors such as obesity and diabetes. XP-102 has the potential to improve liver performance and treat this disease, which currently has no effective medical treatment. Conclusion Xynomic Pharmaceuticals Holdings Inc is a rising biopharmaceutical company that develops innovative cancer drugs. The company has made significant progress since its inception and has an impressive portfolio of cancer therapies. Xynomic Pharmaceuticals works closely with leading partners and academic institutions to develop and provide innovative cancer therapies. The company's products have the potential to change the lives of patients worldwide and offer new treatment options for serious diseases. Xynomic Pharmaceuticals Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Xynomic Pharmaceuticals Holdings's Employee Base

Xynomic Pharmaceuticals Holdings's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Xynomic Pharmaceuticals Holdings's operational capacity and future potential.

Year-to-Year Comparison

Assessing Xynomic Pharmaceuticals Holdings's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Xynomic Pharmaceuticals Holdings's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Xynomic Pharmaceuticals Holdings’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Xynomic Pharmaceuticals Holdings stock

How many employees does Xynomic Pharmaceuticals Holdings have this year?

Xynomic Pharmaceuticals Holdings has 0 undefined employees this year.

How many employees did Xynomic Pharmaceuticals Holdings have compared to the previous year?

Compared to the previous year, Xynomic Pharmaceuticals Holdings had 0% more employees.

What impact did the number of employees have on the company Xynomic Pharmaceuticals Holdings?

The number of employees has a direct impact on the efficiency and productivity of Xynomic Pharmaceuticals Holdings. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Xynomic Pharmaceuticals Holdings?

The number of employees can also have an impact on investors of Xynomic Pharmaceuticals Holdings, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Xynomic Pharmaceuticals Holdings affect the company?

An increase in equity of Xynomic Pharmaceuticals Holdings can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Xynomic Pharmaceuticals Holdings's equity affect the company?

A reduction in equity of Xynomic Pharmaceuticals Holdings can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Xynomic Pharmaceuticals Holdings?

Some factors that can influence the equity of Xynomic Pharmaceuticals Holdings include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Xynomic Pharmaceuticals Holdings so important for investors?

The equity of Xynomic Pharmaceuticals Holdings is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Xynomic Pharmaceuticals Holdings influence the company?

The number of employees at Xynomic Pharmaceuticals Holdings can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Xynomic Pharmaceuticals Holdings evolved in recent years?

In recent years, the number of employees at Xynomic Pharmaceuticals Holdings has changed by NaN.

How many employees does Xynomic Pharmaceuticals Holdings currently have?

Xynomic Pharmaceuticals Holdings currently has 0 undefined employees.

Why is the number of employees important for investors of Xynomic Pharmaceuticals Holdings?

The number of employees is important for investors of Xynomic Pharmaceuticals Holdings as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Xynomic Pharmaceuticals Holdings take to change the number of employees?

To change the number of employees, Xynomic Pharmaceuticals Holdings can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Xynomic Pharmaceuticals Holdings pay?

Over the past 12 months, Xynomic Pharmaceuticals Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Xynomic Pharmaceuticals Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Xynomic Pharmaceuticals Holdings?

The current dividend yield of Xynomic Pharmaceuticals Holdings is .

When does Xynomic Pharmaceuticals Holdings pay dividends?

Xynomic Pharmaceuticals Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Xynomic Pharmaceuticals Holdings?

Xynomic Pharmaceuticals Holdings paid dividends every year for the past 0 years.

What is the dividend of Xynomic Pharmaceuticals Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Xynomic Pharmaceuticals Holdings located?

Xynomic Pharmaceuticals Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Xynomic Pharmaceuticals Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Xynomic Pharmaceuticals Holdings from 11/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/20/2024.

When did Xynomic Pharmaceuticals Holdings pay the last dividend?

The last dividend was paid out on 11/20/2024.

What was the dividend of Xynomic Pharmaceuticals Holdings in the year 2023?

In the year 2023, Xynomic Pharmaceuticals Holdings distributed 0 USD as dividends.

In which currency does Xynomic Pharmaceuticals Holdings pay out the dividend?

The dividends of Xynomic Pharmaceuticals Holdings are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Xynomic Pharmaceuticals Holdings

Our stock analysis for Xynomic Pharmaceuticals Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xynomic Pharmaceuticals Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.